SynoGlia Therapeutics is a biotech company developping stem cell-based platforms for drug discovery against neurodegenerative diseases. Thanks to our technology, we can model complex neurodegenerative diseases using stem cells derived from the patients themselves and harness the power of glial cells to fight neurodegeneration. Our revolutionary platform allows us to conduct "clinical trials-in-a-dish", enabling precision medicine for the next generation of drugs againt neurodegeneration.
Our highly innovative platform will serve to:
1- Accelerate drug development in a field with high unmet clinical need
2- De-risk costly clinical trials and increase overall clinical trials success
3- Reduce the use of animal models
Company Details
- Address
- Lausanne, Ch
- Industry
- Biotechnology
- Website
- https://synoglia.com/
- Keywords
- Neurodegeneration, Precision medicine, Stem cells, Drug development platform, Alzheimer's disease, Multiple sclerosis.
- HQ
- Lausanne
Synoglia Therapeutics Questions
Synoglia Therapeutics's website is https://synoglia.com/
Synoglia Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/synoglia
Synoglia Therapeutics's industry is
Biotechnology
Synoglia Therapeutics's top competitors are
Lirm - Lemanic Institute For Regenerative Medicine,
Lspc - Life Science Poirot Consulting,
Cerebro Gmbh,
Neuroassets Sàrl,
Sport Et Neurosciences,
Lermed,
Fondation Defitech,
Ouroboros Neurotechnologies,
Azurecell,
Nd Biosciences.
Synoglia Therapeutics's categories are Biotechnology
